Kymera Therapeutics, Inc. Common Stock (KYMR) Financials
Key financial figures for Kymera Therapeutics, Inc. Common Stock (Q4 2025).
- Revenue
- $3M
- Net Income
- -$87M
- EPS
- $-0.98
- Total Assets
- $1.7B
- Operating Cash Flow
- -$67M
Full income statement, balance sheet, and cash flow for Kymera Therapeutics, Inc. Common Stock on SentiSense.